1.
Chinese Journal of Nuclear Medicine and Molecular Imaging
;
(6): 689-692, 2021.
Artigo
em Chinês
| WPRIM
| ID: wpr-910819
RESUMO
18F-fluorodeoxyglucose(FDG) PET/MR has been more and more widely used in non-small cell lung cancer (NSCLC). Compared with PET/CT, PET/MR has more advantages, such as higher contrast resolution of soft tissues, less radiation dose and providing physicians with more functional parameters. This article summarizes the application status of 18F-FDG PET/MR in NSCLC in terms of diagnosis, staging, restaging, and prognosis.